

Republic of the Philippines Department of Health FOOD AND DRUG ADMINISTRATION



FDA ADVISORY No. 2020 -805-A

2 JUL 2020

TO:

THE GENERAL PUBLIC

SUBJECT:

Lifting the Advisory on the Registered Food Supplement GOLI NUTRITION APPLE CIDER VINEGAR GUMMIES DIETARY SUPPLEMENT under FDA Advisory No. 2020-805 Subject "Public Health Warning Against the Purchase and Consumption of the Unregistered Food Supplements"

The Food and Drug Administration (FDA) informs the public that the food supplement **GOLI NUTRITION APPLE CIDER VINEGAR GUMMIES DIETARY SUPPLEMENT** has been registered by the Market Authorization Holder, Alphacommerce Corporation in accordance to existing FDA rules and regulations.



Figure 1. Principal Display Panel of the Approved Label of GOLI NUTRITION APPLE CIDER VINEGAR GUMMIES DIETARY SUPPLEMENT (60 pcs.) with registration number FR- 4000006324667 valid until 05 June 2022.

Civic Drive, Filinvest Corporate City, Alabang 1781 Muntinlupa, Philippines
Trunk Line +63 2 857 1900
Fax +63 2 807 0751
Website: www.fda.gov.ph
Email: info@fda.gov.ph











Figure 2. Information Display Panel of the Approved Label of GOLI NUTRITION APPLE CIDER VINEGAR **GUMMIES DIETARY SUPPLEMENT (60pcs)**

Accordingly, the list released in FDA Advisory No. 2020-805 is hereby updated to remove the aforementioned food supplement.

The public is advised to always check if a food product is registered with the FDA. The FDA website (www.fda.gov.ph) has a Search feature which may be used by typing in the name of the product before purchasing. Kindly contact the FDA Center for Food Regulation and Research through e-mail at cfrr@fda.gov.ph, or call (02) 857-1900 loc. 8112 or 8105.

To report any sale or distribution of unregistered food products, the online reporting facility, eReport can be accessed at www.fda.gov.ph/ereport.

The public health warning imposed on the remaining product listed in FDA Advisory No. 2020-805 shall remain to be upheld and shall not be affected by the issuance of this advisory. Furthermore, the issuance of this advisory shall not in any manner preclude this Office from issuing subsequent orders it may deem necessary and appropriate, should there be findings of any violation of the company to the existing laws, rules, and regulations.

Dissemination of this advisory to all concerned is hereby requested.

ROLANDO ENRIQUE D. DOMINGO, MD
Director General